These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36971826)

  • 1. Skin sympathetic nerve activity as a potential biomarker for overactive bladder.
    Chen YC; Chen HW; Huang TC; Chu TY; Juan YS; Long CY; Lee HY; Huang SP; Liu YP; Chen CJ; Wu MN; Chueh KS; Li CC; Lee CH; Tsai WC; Wu WJ
    World J Urol; 2023 May; 41(5):1373-1379. PubMed ID: 36971826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects.
    Hsiao SM; Su TC; Chen CH; Chang TC; Lin HH
    Maturitas; 2014 Sep; 79(1):65-9. PubMed ID: 25022469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of antimuscarinic agents on the activity of the cardiac autonomic nervous system in children with functional overactive bladder.
    Fazeli MS; Pourrahmat MM; Collet JP; Afshar K
    J Pediatr Urol; 2019 Dec; 15(6):642.e1-642.e6. PubMed ID: 31526515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urodynamic evaluation of the efficacy of vibegron, a new β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder.
    Kitta T; Chiba H; Kon M; Higuchi M; Kusakabe N; Ouchi M; Togo M; Abe-Takahashi Y; Tsukiyama M; Shinohara N
    J Pediatr Urol; 2022 Oct; 18(5):563-569. PubMed ID: 35965225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
    Dokmeci F; Cetinkaya SE; Seval MM; Dai O
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Skin Sympathetic Nerve Activity in Patients with Recurrent Syncope.
    Huang TC; Chi NY; Lan CS; Chen CJ; Jhuo SJ; Lin TH; Liu YH; Chou LF; Chang CW; Liao WS; Kao PH; Hsu PC; Lee CS; Lin YH; Lee HC; Lu YH; Yen HW; Lin TH; Su HM; Lai WT; Tsai WC; Lin SF; Lee CH
    J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are patients with the symptoms of overactive bladder and urodynamic detrusor overactivity different from those with overactive bladder but not detrusor overactivity?
    Fan YH; Lin CC; Lin AT; Chen KK
    J Chin Med Assoc; 2011 Oct; 74(10):455-9. PubMed ID: 22036137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
    Seth JH; Sahai A; Khan MS; van der Aa F; de Ridder D; Panicker JN; Dasgupta P; Fowler CJ
    BJU Int; 2013 Mar; 111(3):372-80. PubMed ID: 23444927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.
    Kanagarajah P; Ayyathurai R; Caruso DJ; Gomez C; Gousse AE
    Int Urol Nephrol; 2012 Feb; 44(1):91-7. PubMed ID: 21643644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is overactive bladder a nervous or bladder disorder? Autonomic imaging in patients with overactive bladder via dynamic pupillometry.
    Aydogmus Y; Uzun S; Gundogan FC; Ulas UH; Ebiloglu T; Goktas MT
    World J Urol; 2017 Mar; 35(3):467-472. PubMed ID: 27311587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of heart rate variability in women with overactive bladder syndrome.
    Ben-Dror I; Weissman A; Leurer MK; Eldor-Itskovitz J; Lowenstein L
    Int Urogynecol J; 2012 Aug; 23(8):1081-6. PubMed ID: 22491716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?
    Cornu JN; Grise P
    Curr Opin Urol; 2016 Jan; 26(1):17-21. PubMed ID: 26574877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics.
    Cho KJ; Kim HS; Koh JS; Kim JC
    Int Urogynecol J; 2013 Feb; 24(2):325-30. PubMed ID: 22717785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder.
    Frenkl T; Railkar R; Shore N; Bailen J; Sutherland S; Burke J; Scott BB; Ruddy M; Beals C
    Neurourol Urodyn; 2012 Jan; 31(1):69-74. PubMed ID: 21905086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
    Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
    Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical treatment of female overactive bladder syndrome and treatment-related effects.
    Hsiao SM; Lin HH
    J Formos Med Assoc; 2018 Oct; 117(10):871-878. PubMed ID: 29398096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
    Yüce T; Dökmeci F; Çetinkaya ŞE
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.